The Claim
In adults with type 2 diabetes, treatment with tirzepatide results in a greater reduction in fasting glucagon levels compared to treatment with dulaglutide, and this difference may contribute to improved glycemic control through suppression of hepatic glucose production.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with type 2 diabetes, tirzepatide lowers fasting glucagon levels more than dulaglutide, which may help reduce excessive glucose release from the liver and improve blood sugar control.
See the scientific wording
In adults with type 2 diabetes, tirzepatide reduces fasting glucagon levels more than dulaglutide, which may contribute to improved glycemic control by suppressing inappropriate hepatic glucose production.
Tirzepatide activates two different receptors on the pancreas's alpha cells, which tells those cells to release less glucagon. With less glucagon in the blood, the liver stops making too much sugar, which helps lower blood sugar levels more than drugs that only activate one receptor.
What the research says
1 studyTirzepatide works better than dulaglutide at lowering blood sugar in people with type 2 diabetes, and this is likely because it does a better job of telling the liver to stop making too much glucose — even though the study didn’t measure glucagon directly, the results strongly suggest it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.